Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Coherus is dedicated to expanding patient access to important medicines and delivering significant savings to the U.S. healthcare system.

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Latest News

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

Learn More

Coherus Management to Present at Upcoming Investor Conferences

Learn More

Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

Learn More